I have a history of being deleted in IHub. Below is my last post.
To any new investor in SCRC, the following PRs are just a few that you can read on the ScripsAmerica website. Bob Schneiderman, SCRC CEO, has done an outstanding job building five separate revenue streams to launch SCRC into a huge success in 2014. Funding, read the October 14th PR regarding GEM EMG, an unheard accomplishment for a start up penny stock company. The big news is the expansion of SCRC business into the China market. The SCRC Team travelled to China and we are anticipating hearing news of SCRC tapping into this $32B OTC market. Pediatric Rapimeds is just the beginning. The RapiMed technology is currently being looked at for use in sleep medication, vitamins, and other OTC applications. Projections vary depending on who you talk to, but I can see SCRC hitting the $2 or higher in the next 12 - 16 months. The potential with the China market is huge. Whether you are interested in short term gains or long term profits like a lot of us, SCRC is a stock you do not want to pass up. But, as with any investment , I recommend you do your own DD and make your decision. I originally bought in last March and intend to wait it out for the $2 PPS pay day.
TYSONS CORNER, Va., Oct. 14, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) today announced that it has entered into a financing agreement with GEM Global Yield Fund ("GEM Global"), a member of the Global Emerging Markets Group ("GEM"), to provide funding to the Company of up to $2 million.
TYSONS CORNER, Va., Oct. 23, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) today announced that the Company's acquisition target, PIMD International, launched a new product website www.pimdsupplies.com exclusively to market and sell medical supplies online.
TYSONS CORNER, Va., Oct. 28, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) announced today that the Company's due diligence team will travel to China in November to begin formal RapiMed(R) distribution negotiations in preparation for a product launch into the Chinese OTC market, valued at over $32 billion.
TYSONS CORNER, Va., Nov. 4, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that the Company has received and processed $129,794 in orders during October from its recent pharmaceutical distribution joint venture
TYSONS CORNER, Va., Nov. 11, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that it has agreed to invest in Wholesale Rx "WRx" in exchange for an equity position in the company.
TYSONS CORNER, Va., Nov. 20, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that the Company has satisfied $686,962 in trade payables and outstanding convertible notes in exchange for the issuance of shares of its common stock to Ironridge Consumer Co., a division of institutional investor Ironridge Global IV, Ltd. ("Ironridge") which specializes in direct equity investments in consumer product companies. With $686,962 removed from its balance sheet as a result of this transaction, the financing has paid for ScripsAmerica's cost of goods to supply its RapiMed(R) Children's Pain and Fever Reducer product to retail outlets in China as well as to pay outstanding promissory notes.
To any new investor in SCRC, the following PRs are just a few that you can read on the ScripsAmerica website. Bob Schneiderman, SCRC CEO, has done an outstanding job building five separate revenue streams to launch SCRC into a huge success in 2014. Funding, read the October 14th PR regarding GEM EMG, an unheard accomplishment for a start up penny stock company. The big news is the expansion of SCRC business into the China market. The SCRC Team travelled to China and we are anticipating hearing news of SCRC tapping into this $32B OTC market. Pediatric Rapimeds is just the beginning. The RapiMed technology is currently being looked at for use in sleep medication, vitamins, and other OTC applications. Projections vary depending on who you talk to, but I can see SCRC hitting the $2 or higher in the next 12 - 16 months. The potential with the China market is huge. Whether you are interested in short term gains or long term profits like a lot of us, SCRC is a stock you do not want to pass up. But, as with any investment , I recommend you do your own DD and make your decision. I originally bought in last March and intend to wait it out for the $2 PPS pay day.
TYSONS CORNER, Va., Oct. 14, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) today announced that it has entered into a financing agreement with GEM Global Yield Fund ("GEM Global"), a member of the Global Emerging Markets Group ("GEM"), to provide funding to the Company of up to $2 million.
TYSONS CORNER, Va., Oct. 23, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) today announced that the Company's acquisition target, PIMD International, launched a new product website www.pimdsupplies.com exclusively to market and sell medical supplies online.
TYSONS CORNER, Va., Oct. 28, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (SCRC) announced today that the Company's due diligence team will travel to China in November to begin formal RapiMed(R) distribution negotiations in preparation for a product launch into the Chinese OTC market, valued at over $32 billion.
TYSONS CORNER, Va., Nov. 4, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that the Company has received and processed $129,794 in orders during October from its recent pharmaceutical distribution joint venture
TYSONS CORNER, Va., Nov. 11, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that it has agreed to invest in Wholesale Rx "WRx" in exchange for an equity position in the company.
TYSONS CORNER, Va., Nov. 20, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC), today announced that the Company has satisfied $686,962 in trade payables and outstanding convertible notes in exchange for the issuance of shares of its common stock to Ironridge Consumer Co., a division of institutional investor Ironridge Global IV, Ltd. ("Ironridge") which specializes in direct equity investments in consumer product companies. With $686,962 removed from its balance sheet as a result of this transaction, the financing has paid for ScripsAmerica's cost of goods to supply its RapiMed(R) Children's Pain and Fever Reducer product to retail outlets in China as well as to pay outstanding promissory notes.
